Opko Health, a New York-listed pharmaceutical company, has made a strategic investment of $1m in ChromaDex and acquired the rights to sell its dietary supplements in Latin America.
Opko had previously bought 13% of Fabrus’ outstanding shares in November 2010 as part of a $2.1m round.